



EUROPEAN COMMISSION
HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL

Health systems and products
Medicinal products – authorisations, European Medicines Agency

STAMP 3/13

AGENDA

**3rd Meeting of the Commission Expert Group on
Safe and Timely Access to Medicines for Patients (STAMP)
20 October 2015 (10:00 – 18:00)
Centre A. Borschette, Room AB-4D, Rue Froissart 36,
1040 Brussels, Belgium**

- 1. Opening and adoption of the Agenda**
- 2. Endorsement of the minutes of the 2nd STAMP meeting**
- 3. Regulatory tools for early access:**
 - a. Conditional marketing authorisations (CMA)**
 - Revised CHMP guidelines and summary of comments received during public consultation-[Presentation by the European Medicines Agency \(EMA\)](#)
 - Discussion on legal aspects related to CMA
 - b. Accelerated assessment**
 - Revised CHMP guidelines and summary of comments received during public consultation - [Presentation by EMA](#)
 - New scheme to support development of innovative medicines for unmet needs -[Presentation by EMA and detailed discussion](#)
 - c. Adaptive Pathways**
 - Comprehensive discussion on policy related issues on the basis of current experience from the EMA's pilot project. [Presentation by EMA and detailed discussion](#)
 - EMA's proposal for strategy on registries- [Presentation by EMA and discussion](#)
 - "Prescrire" position paper on adaptive pathways- [Presentation by Ms Teresa Leonardo Alves International Policy Advisor, Prescrire](#)
 - d. Cross-cutting issues for all tools**
 - A holistic approach and communication about all regulatory tools
 - Possible HTA aspects that could be addressed in the regulatory tools for early access under discussion

4. Update on other EU initiatives relevant for timely patient access to innovative medicines

- a. IMI projects- Presentation by Ms Nathalie Seigneuret-Senior Scientific Project Manager, IMI

* * *